Given that the UK has formally announced its decision to leave the EU, what are the implications for...
Read moreMEAs are also known by other names such as risk-sharing agreements, value-added services, and result...
Read moreThe lack of a biosimilar market in the US is largely due to the substantial patent litigations which...
Read moreThis process aims to be completely transparent , to enable faster patient access to oncology treatme...
Read moreBoth payers and physicians do not believe that at the current prices Praluent and Repatha offer sign...
Read moreMulti-criteria decision analysis (MCDA) is a potentially useful tool that can be used to support dec...
Read moreNICE has recently published a consultation on changes to its appraisal process to "fast track" some ...
Read moreThis analysis compares the different methods of seeking payer scientific advice, including EMA joint...
Read moreThe German Ministry of Health has recently published its final bill concerning pricing and market ac...
Read moreBiosimilars have the potential to be considered comparable to generics and offer healthcare benefits...
Read more